Elo Mutual Pension Insurance Co Has $1.87 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Elo Mutual Pension Insurance Co increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 25.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 25,888 shares of the medical equipment provider’s stock after purchasing an additional 5,197 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Hologic were worth $1,866,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Brooklyn Investment Group boosted its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after buying an additional 169 shares during the period. UMB Bank n.a. grew its stake in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after buying an additional 188 shares during the last quarter. Finally, Private Trust Co. NA raised its holdings in Hologic by 19.6% in the 3rd quarter. Private Trust Co. NA now owns 1,166 shares of the medical equipment provider’s stock worth $95,000 after acquiring an additional 191 shares during the period. 94.73% of the stock is owned by institutional investors.

Hologic Trading Down 1.6 %

Shares of Hologic stock opened at $61.32 on Friday. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The firm has a market capitalization of $13.76 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company’s fifty day moving average price is $65.24 and its two-hundred day moving average price is $73.29.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on HOLX shares. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Evercore ISI lowered their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.